Wedbush Issues Pessimistic Forecast for Arcus Biosciences (NYSE:RCUS) Stock Price

07 Nov 2026, 17:07 by Mitch Edgeman · The Markets Daily

Arcus Biosciences (NYSE:RCUS – Get Free Report) had its target price lowered by research analysts at Wedbush from $49.00 to $45.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush‘s target price would indicate a potential upside of 146.62% from the company’s previous close.

Other research analysts have also recently issued reports about the company. JPMorgan Chase & Co. started coverage on Arcus Biosciences in a report on Wednesday, October 14th. They set an “overweight” rating and a $41.00 price objective for the company. Morgan Stanley set a $23.00 target price on shares of Arcus Biosciences in a research note on Monday, August 10th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $42.00 target price on shares of Arcus Biosciences in a report on Friday, August 7th. Wells Fargo & Company increased their target price on shares of Arcus Biosciences from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 6th. Finally, TD Cowen started coverage on shares of Arcus Biosciences in a report on Wednesday, September 16th. They set a “buy” rating for the company. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.36.

Get Our Latest Stock Report on RCUS

Arcus Biosciences Price Performance

Shares of Arcus Biosciences stock traded up $0.56 during midday trading on Thursday, hitting $18.25. 1,055,346 shares of the company were exchanged, compared to its average volume of 2,615,364. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.82 and a quick ratio of 3.82. The firm has a market cap of $2.32 billion, a P/E ratio of -5.03 and a beta of 1.04. Arcus Biosciences has a 52 week low of $17.43 and a 52 week high of $31.74. The firm has a 50 day simple moving average of $23.74 and a 200-day simple moving average of $24.54.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.11). Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The company had revenue of $9.00 million during the quarter, compared to analyst estimates of $7.58 million. During the same period in the prior year, the firm earned ($1.27) EPS. Arcus Biosciences’s quarterly revenue was down 65.4% compared to the same quarter last year. Research analysts forecast that Arcus Biosciences will post -3.55 earnings per share for the current year.

Insider Activity at Arcus Biosciences

In related news, CAO Alexander Azoy sold 2,827 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $30.00, for a total transaction of $84,810.00. Following the sale, the chief accounting officer directly owned 39,581 shares in the company, valued at $1,187,430. This represents a 6.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Arcus Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of RCUS. GAMMA Investing LLC raised its position in Arcus Biosciences by 10.0% in the 2nd quarter. GAMMA Investing LLC now owns 3,966 shares of the company’s stock valued at $122,000 after purchasing an additional 359 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Arcus Biosciences by 1.7% during the second quarter. Arizona State Retirement System now owns 24,211 shares of the company’s stock worth $746,000 after purchasing an additional 409 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Arcus Biosciences by 14.6% during the first quarter. Royal Bank of Canada now owns 4,758 shares of the company’s stock worth $102,000 after purchasing an additional 607 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Arcus Biosciences by 4.1% during the third quarter. Allspring Global Investments Holdings LLC now owns 22,659 shares of the company’s stock worth $572,000 after purchasing an additional 895 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of Arcus Biosciences in the second quarter valued at $30,000. 92.89% of the stock is owned by institutional investors and hedge funds.

Key Arcus Biosciences News

Here are the key news stories impacting Arcus Biosciences this week:

Positive Sentiment: Leerink Partners raised its price target to $49 from $46 and maintained an “outperform” rating, signaling confidence in Arcus’s potential. Read More.
Negative Sentiment: Arcus reported a third-quarter loss of $1.00 per share, wider than analysts’ expected loss of $0.92. Revenue of $9 million exceeded expectations, but was down 65.4% year over year. The earnings-per-share miss may weigh on sentiment. Read More.
Negative Sentiment: Wedbush lowered its price target to $45 from $49, while retaining an “outperform” rating. Truist also trimmed its target, to $40 from $41, but kept its “buy” rating. The reductions temper the positive outlook, though both firms still see substantial potential upside. Read More. · Read More.

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.